ALAB · Nasdaq
The supplied consensus is Buy, but it is based on zero analysts, leaving no meaningful count of supporting recommendations. Its reported mean target is $297, while low and high targets are unavailable, so the evidence provides neither a defensible target cluster nor a measurable spread; the mean is below the latest close of $361.67. No most- or least-bullish analyst can be identified from that consensus. The only explicitly attributable revision in the supplied material is JPMorgan's increase of its Astera Labs target to $280 from $205, but no date is provided, so the evidence cannot establish that revisions moved during the past week. The substantive disagreement is growth and AI demand versus valuation, competition, and margin risk.
